title: Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
abstract: BACKGROUND
  Patients with severe or complicated reflux disease may require higher than standard doses of a proton pump inhibitor for sufficient acid suppression.
  
  
  OBJECTIVE
  To test the hypothesis that esomeprazole 40 mg twice daily is superior to pantoprazole 40 mg twice daily in lowering intragastric acidity.
  
  
  METHODS
  In a randomized, single-blinded, two-way crossover study, healthy subjects received esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily orally for five consecutive days. Continuous ambulatory 24-h intragastric pH was recorded on day 5 of each treatment.
  
  
  RESULTS
  Thirty subjects were analysed. Esomeprazole provided significantly higher intragastric pH-values over the 24-h period [median intragastric pH 6.4 for esomeprazole and 5.1 for pantoprazole (P < 0.00005)]. Intragastric pH > 4 was maintained for 21.1 h with esomeprazole and 16.8 h with pantoprazole (P < 0.0001). An intragastric pH > 4 for more than 16 h was achieved in 96.7 and 56.7% of subjects, respectively (P = 0.0002). During night-time the proportion of time with intragastric pH > 4 was 85.4% with esomeprazole and 63.6% with pantoprazole (P = 0.0001). Nocturnal acid break through occurred less frequently on esomeprazole.
  
  
  CONCLUSIONS
  Esomeprazole 40 mg twice daily provides better and more consistent intragastric acid control than pantoprazole 40 mg twice daily.
authors.affiliation: Medical Department I, Technical University Hospital Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. stephan.miehlke@uniklinikum-dresden.de
authors.forename: S
authors.initials: S
authors.lastname: Miehlke
authors.forename: A
authors.initials: A
authors.lastname: Madisch
authors.forename: C
authors.initials: C
authors.lastname: Kirsch
authors.forename: F
authors.initials: F
authors.lastname: Lindner
authors.forename: E
authors.initials: E
authors.lastname: Kuhlisch
authors.forename: M
authors.initials: M
authors.lastname: Laass
authors.forename: H
authors.initials: H
authors.lastname: Knoth
authors.forename: A
authors.initials: A
authors.lastname: Morgner
authors.forename: J
authors.initials: J
authors.lastname: Labenz
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D064098:Esomeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D016037:Single-Blind Method; D013454:Sulfoxides / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D064098:Esomeprazole